seratinib

Seratinib (QLH11906) is an orally bioavailable, irreversible pan-HER tyrosine kinase inhibitor (TKI) developed by Qilu Pharmaceutical. It targets the human epidermal growth factor receptors EGFR (HER1), HER2, and HER4. By covalently binding to the ATP-binding site of these receptors, seratinib inhibits their autophosphorylation and downstream signaling pathways, such as PI3K/Akt and MAPK, which are critical for the proliferation and survival of HER2-amplified or EGFR-mutated cancer cells. It is primarily being investigated for the treatment of advanced HER2-positive breast cancer and other solid tumors expressing HER family members.

Other names

pan-RAF inhibitor QLH11906